Pfizer, Inc. 보도자료 - 뉴스와이어

기업 뉴스룸

Pfizer, Inc.

제약

NEW YORK

Pfizer, Inc. 보도자료

13개

RSS 이메일

2016년 1월 5일 10:20

Merck, Pfizer and Syndax Announce Collaboration to Evaluate Combination of Avelumab and Entinostat in Ovarian Cancer

Merck, Pfizer and Syndax Pharmaceuticals, Inc. announced today that they have entered into a collaboration agreement to evaluate avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Syndax’s entinostat, a

건강 제약 제휴

2015년 12월 23일 10:30

Merck and Pfizer Advance Clinical Development Program with Two Additional Phase III Trials of Avelumab

Merck and Pfizer today announced the opening of trial sites for an international Phase III study of avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in patients with platinum-resistant/refractory ovarian cancer. The JAVE

건강 제약 개발

2015년 12월 10일 13:55

Merck and Pfizer Initiate Two Phase III Studies of Investigational Immunotherapy Avelumab in Advanced Gastric and Gastro-esophageal Junction Cancers

Merck and Pfizer today announced the initiation of two Phase III studies of avelumab*, an investigational, fully human anti-PD-L1 IgG1 monoclonal antibody, in treating advanced or metastatic gastric/gastro-esophageal junction (GEJ) cancers, which are

건강 제약 개발

2015년 11월 24일 10:25

Pfizer and Allergan to Combine

Pfizer Inc. (NYSE:PFE) and Allergan plc (NYSE:AGN) today announced that their boards of directors have unanimously approved, and the companies have entered into, a definitive merger agreement under which Pfizer, a global innovative biopharmaceutical

건강 제약 인수/합병

2015년 11월 19일 10:50

Pfizer Reports Positive Topline Results from Phase 3 Trial Comparing XALKORI® (crizotinib) to Chemotherapy in Previously Untreated East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Pfizer Inc. announced today that PROFILE 1029, a Phase 3 study of anaplastic lymphoma kinase (ALK) inhibitor XALKORI® (crizotinib), met its primary objective of significantly prolonging progression-free survival (PFS) in previously untreated East Asi

건강 제약 개발

2015년 11월 19일 10:45

Merck and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma

Merck and Pfizer today announced that the US Food and Drug Administration (FDA) has granted avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, Breakthrough Therapy designation for the treatment of patients with metastatic

건강 제약 수상/선정

2015년 11월 5일 12:10

Merck and Pfizer Announce Initiation of Phase III First-Line Trial of Avelumab in Patients with Recurrent or Stage IV Non-Small Cell Lung Cancer

Not intended for UK-based media Merck and Pfizer today announced the initiation of an international Phase III study of the investigational cancer immunotherapy avelumab* in a treatment naïve advanced NSCLC setting. The study, JAVELIN Lung 100, is

건강 제약 개발

2015년 10월 8일 17:45

Merck and Pfizer Announce Investigational Immunotherapy Avelumab Receives FDA Fast Track Designation for Metastatic Merkel Cell Carcinoma

Merck and Pfizer today announced that the US Food and Drug Administration (FDA) has granted avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, Fast Track designation for the treatment of metastatic Merkel cell carcinoma (M

건강 제약 개발

2015년 10월 8일 17:45

머크-화이자, 전이성 메르켈세포암 치료 위한 임상용 면역치료제 아벨루맵의 FDA 신속심사 자격획득 발표

머크(Merck)와 화이자(Pfizer)가 오늘 미국 식품의약국(US Food and Drug Administration, 이하 FDA)이 임상용 인간 항-PD-L1 IgG1 단클론 항체인 아벨루맵(avelumab*)을 희귀하고 공격적인 피부암의 일종인 전이성 메르켈세포암(Merkel cell carcinoma, 이하 MCC) 치료를 위한 신속심사(Fast Track) 대상으로 지정됐다고 발표했다.[1,2]

건강 제약 개발

2015년 9월 29일 13:00

Merck and Pfizer Announce FDA Orphan Drug Designation for Investigational Immunotherapy Avelumab in Merkel Cell Carcinoma

Merck and Pfizer today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation for the investigational cancer immunotherapy avelumab* for the treatment of Merkel cell carcinoma (MCC), a rare and aggressive type of

건강 제약 개발

2015년 9월 25일 10:15

Merck and Pfizer Collaborate with Dako, an Agilent Technologies Company, on Development of Companion Diagnostic for Investigational anti-PD-L1 Antibody, Avelumab

As part of the global strategic alliance between Merck and Pfizer to jointly develop and commercialize avelumab*, an investigational immune checkpoint inhibitor, the companies have announced today that they have a collaboration agreement in place wit

건강 제약 제휴

2015년 9월 11일 18:50

Merck and Pfizer to Present Updates for Avelumab at the European Cancer Congress 2015

Merck and Pfizer today announced that six abstracts on studies evaluating the potential role of programmed death-ligand 1 (PD-L1) inhibition and the safety and efficacy of the investigational cancer immunotherapy avelumab* will be presented at this y

건강 제약 행사

2015년 5월 14일 12:00

Merck and Pfizer to Present Data at ASCO for Avelumab, an Investigational Anti-PD-L1 Antibody

Merck and Pfizer today announced multiple presentations on studies evaluating the preliminary safety and efficacy of avelumab* at the 2015 American Society of Clinical Oncology (ASCO) annual meeting. Avelumab (also known as MSB0010718C) is an inve

건강 제약 개발